echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > NEJM: Can anti-IL-6R antibody Tocilizumab treatment improve the prognosis of patients with severe new coronary pneumonia?

    NEJM: Can anti-IL-6R antibody Tocilizumab treatment improve the prognosis of patients with severe new coronary pneumonia?

    • Last Update: 2021-03-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Coronavirus disease

    Coronavirus disease

    Case reports and retrospective observational cohort studies suggest that treatment with tocilizumab (tocilizumab), an anti-interleukin-6 receptor monoclonal antibody, can improve the prognosis of patients with severe new coronary pneumonia.


    In this phase 3 trial, researchers randomly divided hospitalized patients with severe new coronary pneumonia into two groups at 2:1, and received a single intravenous infusion of tocilizumab (8 mg/kg) or placebo.


    A total of 452 patients were randomized, of which 438 (294 in the tocilizumab group and 144 in the placebo group) entered the first and second analyses.


    On the 28th day, the median values ​​of the clinical status of the tocilizumab group and the placebo group were 1.


    In short, in this randomized trial of patients with severe new coronary pneumonia, treatment with tocilizumab did not significantly improve the clinical condition of patients at 28 days or reduce mortality.


    Treatment with tocilizumab did not significantly improve the patient's clinical condition at 28 days or reduce mortality.


    Original source:

    Rosas Ivan O, Brou Norbert, Waters Michael et al.


    org/10.
    1056/NEJMoa2028700">Tocilizumab in Hospitalized Patients with Severe Covid- 19 Pneumonia in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.